# Dietitians Using GLP-1s Push Back Against Weight-Loss Stigma
GLP-1 receptor agonists like semaglutide and tirzepatide have become synonymous with rapid weight loss, but registered dietitian nutritionists who take these medications themselves are working to reshape the public conversation around their clinical uses and benefits.
The stigma surrounding GLP-1 drugs stems largely from celebrity endorsements and media coverage focused exclusively on cosmetic weight loss. This framing obscures what research demonstrates about their broader therapeutic applications. GLP-1 drugs were originally developed to treat type 2 diabetes by mimicking glucagon-like peptide-1, a hormone that regulates blood sugar and appetite. The weight loss effects emerged as a secondary benefit during clinical trials.
Dietitians who use GLP-1s argue that the medications serve multiple physiological functions beyond fat reduction. They improve insulin sensitivity, reduce inflammation, lower cardiovascular risk markers, and improve glycemic control in people with metabolic disease. Some research suggests potential benefits for heart health in non-diabetic populations as well, though long-term safety data continues to emerge.
Several registered dietitians have publicly discussed their own GLP-1 use, framing it not as a shortcut but as a tool within a broader health management strategy. Their perspective carries weight in a profession that has historically emphasized diet and exercise alone. By acknowledging their own use, these practitioners normalize the medication and position it within evidence-based medicine rather than celebrity culture.
The professional resistance to GLP-1s within certain nutrition circles reflects legitimate concerns. These medications require ongoing use to maintain effects, carry potential side effects like nausea and gastrointestinal distress, and can be financially inaccessible at list prices exceeding $1,000 per month. Additionally, some clinicians worry about patients using GLP-1s as replacements for sustainable lifestyle changes rather than adjuncts to them.
However, dietitian advocates emphasize that this is a false choice. For people with type 2 diabetes, prediabetes, or obesity complicated by metabolic dysfunction, GLP-1s can stabilize blood sugar and reduce appetite drive while they work with clinicians and nutritionists on dietary pattern change. The medication creates a window for behavior modification that might otherwise remain impossible due to dysregulated hunger hormones and metabolic resistance.
The conversation parallels debates surrounding other chronic disease medications. Statins reduce cardiovascular risk but do not eliminate the need for dietary improvements. Antihypertensive drugs manage blood pressure alongside lifestyle interventions. Yet GLP-1s face heightened scrutiny, partly because weight and body size remain deeply moralized rather than treated as neutral health metrics.
Registered dietitians taking GLP-1s send a clear message: clinical medications have clinical purposes. Using them does not indicate failure or laziness. It reflects a pragmatic approach to metabolic health that integrates pharmacology, nutrition science, and behavioral change.
This reframing matters for public health. Millions of adults with metabolic disease struggle with glucose control and weight management despite sincere efforts with diet and exercise alone. Reducing stigma around GLP-1 medications removes barriers to evidence-based treatment and allows conversations to focus on patient outcomes rather than moral judgments about pharmaceutical use.